Avandamet Supply Issues Are Resolved, Allowing Launch Of New Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline's announcement about renewed Avandamet availability follows the approval of the type 2 diabetes drug for first-line use.
You may also be interested in...
Avandia Not Losing Market Share To Januvia, GSK Reports
Merck’s DPP-4 inhibitor is largely taking business from metformin and sulfonylureas, GSK exec Stout asserts.
Avandia Not Losing Market Share To Januvia, GSK Reports
Merck’s DPP-4 inhibitor is largely taking business from metformin and sulfonylureas, GSK exec Stout asserts.
Avandamet sNDA Approved For First-Line Use In Type 2 Diabetics
GlaxoSmithKline’s updated label for the rosiglitazone/metformin combination also includes new data concerning risk in congestive heart failure patients.